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Abstract
During the 2014–2015 Ebola outbreak in Guinea, Liberia and Sierra Leone, many opposed the use 
of individually randomised controlled trials to test candidate Ebola vaccines. For a raging fatal 
disease, they explained, it is unethical to relegate some study participants to control arms. In Zika 
and future emerging infections, similar opposition may hinder urgent vaccine research, so it is best 
to address these questions now. This article lays out the ethical case for individually randomised 
control in testing vaccines against many emerging infections, including lethal infections in low-
income countries, even when at no point in the trial do the controls receive the countermeasures 
being tested. When individual randomisation is feasible—and it often will be—it tends to save 
more lives than alternative designs would. And for emerging infections, individual randomisation 
also tends as such to improve care, access to the experimental vaccine and prospects for all 
participants relative to their opportunities absent the trial, and no less than alternative designs 
would. That obtains even under placebo control and without equipoise—requiring which would 
undermine individual randomisation and the alternative designs that opponents proffered. Our 
arguments expound four often-neglected factors: benefits to non-participants, benefits to 
participants once a trial is over including post-trial access to the study intervention, participants’ 
prospects before randomisation to arms and the near-inevitable disparity between arms in any 
randomised controlled trial.
At the height of the recent Ebola outbreak in West Africa, a debate emerged:i how to test the 
efficacy of candidate Ebola treatments and vaccinations? Should investigators randomise 
individual participants to receive either the relevant countermeasure or a control substance?
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The debate was partly about statistical efficiency, logistical feasibility and public 
acceptability and partly about ethics.12 In particular, some commentators argued that given 
Ebola’s high lethality and few, if any, available clinical alternatives, it would be unethical to 
randomise participants to a control arm.
This ethical objection typically affected individually randomised controlled trials 
(iRCTs).1–6 Critics were softer on cluster-randomised trials.5 While the objection focused 
especially on treatment iRCTs and while vaccine iRCTs usually recruit individuals who are 
uninfected and thus, in the case of Ebola, at much lower risk of imminent death, many points 
made against treatment iRCTs would seem applicable to vaccine iRCTs. Ebola vaccine 
iRCTs often recruited health workers at high risk of infection.7 Accordingly, ethicist Ruth 
Macklin wondered whether an argument against (placebo-controlled) iRCTs for treatments 
should not also apply to iRCTs for vaccines.8 The distinction between treatment and vaccine 
trials was elided in the popular press,9 and ethical opposition to either placebo- or active-
controlled iRCTs undergirded high-level debates on vaccine trials.110 Specifically, it was 
reported that
Doctors Without Borders (MSF), which has treated more Ebola patients in West 
Africa than any other group, emphatically opposes RCTs in affected countries for 
either treatments or vaccines. MSF’s Annick Antierens, who oversees 
‘investigational platforms’ for experimental Ebola products, says ‘this cannot be 
defended ethically.’2
A recent commentary persists in criticising individually iRCTs of Ebola vaccines, claiming 
that ‘access to experimental interventions should have higher priority over the use of a 
randomized clinical trial design for [Ebola] vaccine efficacy studies’.11 As with other 
aspects of preparedness for Zika and for future infections, the time to debate the ethics of 
vaccine iRCTs for these emerging diseases is now.
This article argues that iRCTs made ethical sense in prospect for Ebola vaccines and will 
typically make ethical sense for testing future emerging-infection vaccines.
THE LIKELY EFFICIENCY OF IRCTS MATTERS ETHICALLY
Let us revisit the case of vaccine iRCTs for Ebola. At the time of the debate in autumn 2014, 
Ebola was out of control in the three affected countries. WHO had projected up to thousands 
of new infections a week12 and the US Centers for Disease Control and Prevention had 
projected up to 1.4 million infections by the end of that year.13 The heads of the Wellcome 
Trust and America’s National Institute of Allergy and Infectious Disease were losing hope in 
traditional public health measures of containment and conjectured that ‘a vaccine might be 
the only way left to suppress the outbreak’.13 Any delay in generating credible results from 
vaccine efficacy trials might have been estimated to cost many deaths from Ebola—
potentially in the thousands. Thousands more expectedly died from the consequent loss of 
other medical and preventative services.14 Vaccines were already in early stages of 
iFor comments on earlier iterations of this paper we thank Mosoka Fallah, Leah Price, Annette Rid, Esha Senchaudhuri, Dan Wikler, 
and audiences at the 2015 Beth-Israel Deaconess Symposium on Global Response to Emerging Infections and the 2016 Brocher 
Summer Academy on Global and Population Health, as well as anonymous referees.
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development and both iRCT proponents and iRCT opponents agreed that an iRCT is the 
‘gold standard’ of medical research, which usually produces the quickest credible data on 
vaccine efficacy.315 But at the time, some prominent humanitarian workers, leaders, 
epidemiologists and ethicists considered iRCTs unnecessary, non-feasible and possibly 
unethical.1
No one advocated foregoing altogether either vaccine development or the assessment of 
vaccine candidates’ efficacy before rollout. Instead, four main categories of ‘alternatives’ for 
assessing the efficacy of Ebola vaccine candidates were proposed. Two that are not worth a 
detailed discussion as iRCT alternatives are comparison to historical controls,16 which was 
quickly seen to be impossible for vaccine trials in view of the abrupt and unpredictable 
spatiotemporal changes in Ebola transmission during the outbreak1 and sequential and 
adaptive designs (to test treatments),5 which in fact are perfectly compatible with individual 
randomisation.17
But two cluster-randomised trial designs were also proposed: the stepped-wedge design1 and 
a novel ring-vaccination design.18 Unlike iRCTs, they were said to avoid randomising any 
participants to a placebo or other control. Instead they offer vaccine to all participants, using 
variation of timing for scientific comparison.
In a stepped-wedge design, all participants receive the vaccine candidate at different points 
in time. Investigators compare disease incidence among participants who had not yet 
received it against the incidence in those who had. iRCT opponents were ‘“more 
comfortable” with the stepped-wedge design, because everyone in such a study would get 
the Ebola vaccine.’1
Ring vaccination, a strategy previously used for the final stages of smallpox eradication, was 
first used for a randomised vaccine trial during this Ebola outbreak. A ring-vaccination trial 
in Guinea enrolled both contacts of a confirmed case and these contacts’ contacts (together 
called a ‘ring’) and randomised each ring to either immediate vaccination or vaccination 3 
weeks later, to provide a comparison. When the Guinea ring-vaccination trial yielded 
evidence of the effectiveness of a candidate vaccine for Ebola,18 there were immediate calls 
to use this investigational strategy for vaccine trials in future disease outbreaks,19 partly 
because, by contrast with an iRCT, all participants were offered the candidate vaccine under 
study at some point in the trial.19
Nonetheless, the following reasoning would have arguably made sense when the Ebola 
iRCTs debate began, and analogous reasoning will make sense for many emerging future 
infections:
Fighting this infection to win requires evaluating interventions ‘in the best possible 
clinical trials under the circumstances in order to definitively prove their safety and 
efficacy or provide evidence to stop utilization’.20 If in the circumstances the 
method likeliest to produce credible-enough data fast turns out to be an iRCT, as it 
typically is in vaccine efficacy trials,21 there is a strong presumption in favour of 
conducting an iRCT. Choosing an iRCT is not ‘doggedly insisting on gold 
standards’;3 rather, successful iRCTs will speed up responsible mass-scale delivery 
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of tested vaccines. Only some rough estimate of efficacy levels would enable health 
ministries to match vaccine penetration to herd immunity needs. Only robust trial 
outcomes would lend earlier credibility to calls on the public to undergo the 
vaccination and on donors to invest large amounts to buy and deliver vaccines. In 
this circumstance, non-iRCT designs risk mistaking confounders for vaccine effects 
or missing a true effect of the vaccine due to inadequate power. We might vaccinate 
a large population only to discover that we have burdened or harmed them for little 
or no protection.22 Sceptical populations might later come to distrust even 
countermeasures that had been properly tested before rollout.23 Alternatively, if the 
cluster-randomized trial’s size or duration is increased to keep It valid in settings of 
fluctuating and unpredictable incidence, then more time and more infections in the 
trial will typically be required before it can draw a conclusion. Admittedly, if 
weaker methods turn out to yield estimates of nearly 100% effectiveness or nearly 
0% effectiveness with narrow confidence bounds, even they could tell us credibly 
what to do. But if, as is usually the case,22 they do not, we will have lost months, 
and many lives, to the disease.
This article remains largely agnostic on trial design methodology and feasibility challenges 
in iRCTs (though see Appendix A: feasibility) Indeed, the circumstances of future emerging 
infections remain somewhat unpredictable. Instead, it argues conditionally that if in Ebola or 
in a future outbreak, after open-minded consideration of statistical and practical challenges 
and their potential solutions, an iRCT continues to carry by far the greatest promise to help 
vaccines save as many lives as possible, then normally a vaccine iRCT would be perfectly 
ethical and should be conducted. Nothing bars vaccine iRCTs from treating ethically 
everyone, study controls included and even from giving controls the best prospects while 
maintaining validity. In some ways, iRCTs that give the entire community, and not just study 
participants, the best prospects under the circumstances are fairer than alternative designs.
Our argument proceeds as follows. We start by noting a few common attributes of to all 
these competing designs for efficacy trials of vaccines against Ebola and against other 
emerging infections. We then argue that the medical care of all participants, including study 
controls, may benefit indirectly from inclusion in such a trial. We add that participants’ 
access to the study intervention may improve in an iRCT more than under the alternative 
designs. We then show that all participants’ medical prospects prior to randomisation may 
improve from inclusion, which we claim is what matters the most. We address the objection 
that even if participants benefit, iRCTs fail at the bar of equipoise. And we end by 
generalising these conclusions to vaccine tests for most emerging infections.
IRCTS AND THE ALTERNATE DESIGNS SHARE SOME PARTIAL 
JUSTIFICATIONS
Table 1 below reviews the compatibility of iRCTs and of the alternate cluster-randomised 
study designs under consideration with several conditions. The first two columns designate 
iRCTs, with placebo (eg, saline injection) and with active control (a proven vaccine against 
another disease). The final column designates the cluster-randomised stepped-wedge and 
ring-vaccination designs. Each row reviews whether some ethically relevant condition could 
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characterise Ebola vaccine efficacy trials during the outbreak, for each trial design. A tick 
sign means that a trial of the given kind could be designed to fulfil the criterion (not that 
every trial of this kind necessarily would), and a minus sign, that it could not.
The first three rows state three obvious common denominators. Any of these trial designs 
would answer a very pressing public health need (table 1 row 1a); in none of these designs 
was serious toxicity expected in either arm—all were efficacy trials following a trial to rule 
out major toxicity (1b) and because no vaccine against Ebola existed when the trials began 
(1c), no design (not even placebo-controlled iRCT) deprived participants of an intervention 
to which they would have access or straightforward moral entitlement otherwise.
IN AN IRCT, ALL PARTICIPANTS’ CARE MAY IMPROVE RELATIVE TO NO 
TRIAL PARTICIPATION
Participation in a vaccine iRCT against an emerging infection can be medically beneficial to 
all participants, study controls included. During the 2014 Ebola outbreak, participants in 
either arm of a vaccine efficacy iRCT would usually receive better supportive care in the 
trial than they would have in the chaotic surrounding system and better than many others 
actually received.24 By nature, trials involve close surveillance for new infections. This 
could also benefit participants in either arm because early treatment of an infection typically 
improves patient outcomes,25 and reduces his or her risk of infecting family.26 Another 
benefit to all participants would be that, as in any experimental vaccine trial, intensive 
education on protective measures would be necessary so as to counteract a false sense of 
safety, and such intensive education would rarely be available outside the studies. For Ebola 
(and for many future emerging infections in low/middle-income countries), neither these 
benefits nor a proven active vaccine and the candidate vaccine were (or will be) available 
outside the trial. Indeed, even in the hardest case, that of placebo-controlled trial, no one 
would forego active vaccination to accept placebo (table 1, rows 1b–c).15 And participants 
randomised to the control arm in an iRCT would accrue additional benefits when the control 
substance is a proven vaccine against another endemic disease, such as, in the recent 
outbreak, hepatitis B.1
IN AN IRCT, ALL PARTICIPANTS’ ACCESS TO THE EXPERIMENTAL 
VACCINE MAY IMPROVE RELATIVE TO NO TRIAL PARTICIPATION, NO 
LESS THAN UNDER ALTERNATIVE DESIGNS
Recall that opponents preferred stepped-wedge and the ring-vaccination design primarily 
because ordinarily in both active—and placebo-controlled iRCTs, no control receives the 
study intervention during the trial.
But compare iRCTs to the proposed alternatives in terms of participant access to the study 
intervention (table 1 rows 2a–c). All stepped-wedge and ring-vaccination designs withhold 
vaccines from some participants for some time.127 Indeed, they assess vaccine effectiveness 
precisely by comparing those who receive the vaccine candidate early to those who receive it 
late. While opponents could have explained better late than never, for some in the alternate 
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designs vaccination would come too late. Crudely put, some participants in stepped-wedge 
and ring-vaccination trials will die or get infected, or the trial might end, before the vaccine 
candidate reaches them (table 1 row 2a).28
It may still seem as though stepped-wedge and ring-vaccination trials are less harsh: iRCT 
opponents might insist that although for a few participants of stepped-wedge and ring-
vaccination trials, late would mean never, it remains the case that better never for a few and 
late for some others than never for any study controls.427
But nothing about iRCTs precludes bringing the study intervention to everyone at some 
point, either. Both placebo and active control iRCTs are perfectly compatible with granting 
access to any available candidate vaccine shortly or immediately after the trial, potentially 
before vaccine approval (table 1 row 2b). Indeed, the delay in granting participants universal 
access to the vaccine candidate within an iRCT may be shorter than in stepped-wedge and 
ring-vaccination trials. This is because, typically, an iRCT is more efficient than cluster-
randomised alternatives for measuring a particular effect size, so an iRCT can be completed, 
all else equal, in less time and with fewer infections in the trial population. Hence, typically, 
the number of participants who will die or get infected before the study intervention reaches 
them is going to be smaller in participant-friendly iRCTs than in participant-friendly 
stepped-wedge and ring-vaccination trials (table 1 row 2c).
It seems mistaken to focus on the potential of stepped-wedge and ring-vaccination designs to 
benefit participants more while the trial lasts (table 1 row 2a); iRCTs can be made to benefit 
participants more, overall (table 1 row 2c), and that seems more important.
Post-trial access to the study intervention is usually debated as a requirement for ethical 
trials independent of the requirement for a favourable risk–benefit ratio. Our argument 
points out that the former affects the latter. Indeed, as the number of candidate interventions 
being tested increases, the proportion of participants randomised to the best candidate 
intervention declines and post-trial access to the best candidate interventions may turn out to 
be the main benefit for most randomised trial participants. As noted, iRCTs normally require 
fewer infections in the trial to achieve a given degree of statistical power. Therefore, giving 
controls an effective study vaccine immediately on the end of an iRCT would ordinarily 
mean that fewer infections occurred in the trial population (and, for a given incidence rate, 
less time would have passed) than would have occurred in a cluster-randomised trial of 
equivalent power.
IN AN IRCT, ALL PARTICIPANTS’ PROSPECTS PRIOR TO RANDOMISATION 
MAY IMPROVE RELATIVE TO NO TRIAL PARTICIPATION, NO LESS THAN 
UNDER ALTERNATIVE DESIGNS
In table 1, rows 3a–e review how the competing trial designs fare on several standards for 
improvement to participants’ medical prospects. Table 1 Row 3a registers the capacity of 
each design to improve medical prospects for all participants more than any alternative 
available outside the trial. The previous two sections argued that iRCTs can improve the 
prospects of participants in all arms after randomisation. Even if these sections are wrong, 
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the present section adds that iRCTs can improve prospects of participants in all arms prior to 
randomisation to arms, and that this may be what matters the most.
Suppose that for some reason, placebo were used for control, there were no post-trial access, 
and participants received neither education, money nor accelerated/better treatment if 
infected, or any other indirect benefits. If safety-tested vaccine candidates were available 
only in the trial, and only in its active arm, participation would still usually improve an at-
risk individual’s prospect of net benefit, appropriately assessed, for a simple reason.
Before randomisation to arms, every participant of a placebo-controlled efficacy trial gains a 
substantial chance of winding up on the active arm, with potential protection—if randomised 
to that arm. Given that no arm (including control) exposes participants to worse prospects 
than they would have outside the trial (condition 1b in table 1), it follows that all participants 
achieve medical prospects superior to the ones that they would have had otherwise and 
superior to those of at-risk non-participants. An influential 2014 letter proclaimed against 
Ebola treatment iRCTs, ‘None of us would consent to be randomised in such 
circumstances’;3 and others concurred.523 However, for anyone at high risk of exposure and 
offered either no Ebola countermeasure or a substantial chance of getting an experimental 
countermeasure that showed animal evidence of protection and passed safety tests, declining 
the offer would be unwise.
iRCT opponents might retort to our emphasis on the prospects before randomisation that all 
participants have a right to ‘actual’ intervention, not just to dramatically improved advance 
prospects. We disagree. The point of even clinical care is never simply intervening; it is 
improving medical prospects. And better prospects are what iRCTs give to every participant. 
What more might be owed to participants? Not improved outcomes. Many promising-
looking vaccines and therapeutics turn out on testing to have been ineffective or harmful and 
that does not make their testing unethical. Even in clinical care, we use procedures and drugs 
known to carry some severe risks, and their utilisation is justified notwithstanding occasional 
severe injuries or deaths when their prospect of benefiting far exceeds that of harming.
On a broader note, recent research in ethics explores multiple potential reasons—of fairness, 
of compassion, of solidarity and still others—to heed the distribution of personal prospects 
and that of personal outcomes.29 It is time that these considerations inform the longstanding 
debate about the ethics of randomised and placebo control. A high chance of being 
randomised to the best treatment is important for the same basic reason that getting the best 
treatment is important: it improves one’s medical prospects.
Our opponents may reply that what is owed is the very best possible medical prospects 
available to anyone, for example, per Western standards of care—not just better prospects 
that would be available to the candidate participant outside the trial. But even the opponents’ 
preferred alternatives to iRCTs, including stepped-wedge and ring-vaccination designs, 
failed to provide the best possible medical prospects (table 1 row 3b). In either stepped-
wedge or ring-vaccination designs, participants randomised to have the vaccine withheld 
until a later time would have benefited even more from immediate receipt of the safety-
tested vaccine, and the added protection against the outbreak that would come with that.2728
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Our position is not that improvement in a participant’s prospects prior to randomisation can 
justify any treatment after randomisation. The following vaccine efficacy study would be 
unacceptable although it may advance science and improve the candidate participant’s 
prospects compared with his or her alternatives: in a study of a very promising Ebola 
vaccine candidate, one small arm among many is injected with that vaccine candidate, laced 
with live Ebola virus infection. If the proportion of patients in this diabolical arm was small 
enough, participations in the trial might improve their prospects prior to randomisation, yet 
clearly, the trial remains unacceptable. Recall, however, point 1b in table 1: our entire 
discussion is premised on the assumption that in no arm are participants expected to 
experience harm relative to non-participants; our position is only that when condition 1b is 
met (as are conditions 1a and 1c), risk–benefit ratios are no more adverse in iRCTs than in 
the alternate designs. We do not weigh in on trials violating these conditions.
And while some may insist that individual control (at least individual placebo control) is 
diabolical enough to be treated as if it were causing active harm to controls, that seems 
deeply implausible in vaccine trials. In such trials, the subjects are presumed uninfected and 
they are, at worst, treated like uninfected patients outside the trials. Some of our points in the 
next paragraph further address this response.
Some have argued for promoting participants’ prospects so long as the compromise of 
scientific validity remains moderate,4 or nil.27 But even if validity remains intact, promoting 
participants’ prospects further could still substantially compromise trial efficiency, 
understood as duration and/or number of infections in the trial required to reach the desired 
degree of statistical power. In trials of countermeasures against Ebola (and in ones against 
many future infections), postponing the degree of knowledge that permits rollout could cost 
many deaths and injuries, and compassionate4 researchers will factor in those calamities as 
well. Indeed, pitting rigour against compassion is simply misguided here. As explained 
above, iRCTs can be better than the alternative designs even for participants. Moreover, the 
entire impetus for benefiting participants as much as possible has been said to be 
misguided.30 And finally, because in this setting, participation already improves medical 
prospects for each participant enough to make them superior to those of non-participants at 
similar risk (table 1 row 3c), to insist on giving participants more at the expense of bringing 
protection to non-participants whose prospects are worse (eg, to non-participating health 
workers) would have only exacerbated a disparity.
REQUIRING EQUIPOISE WOULD THWART BOTH IRCTS AND THE 
ALTERNATE STUDY DESIGNS
In clinical trial design,
Equipoise is the point where there is no preference between treatments, i.e. it is 
thought equally likely that treatment A or B will turn out to be superior… At this 
point we… would take odds of 1:1 in a bet. Equipoise is different from simply not 
‘knowing’ or being ‘uncertain’, because it implies that we have no (rational) 
preference whatever.31
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In different versions of the equipoise requirement, that lack of rational preference is on the 
parts of the investigator, the medical community or study participants.31–34 For 
investigational Ebola vaccines in 2014, with animal evidence of efficacy, evidence of safety 
and immunogenicity in humans, and no alternative vaccine available, prospects were clearly 
better in the active arm, from any of these viewpoints.8 iRCT opponents have added, 
normatively, that this lack of equipoise is unacceptable.568
Yet, in the Ebola vaccine case, both iRCTs and alternatively designed trials lacked equipoise 
(table 1 row 3d). Stepped-wedge and ring-vaccination also involved a comparison between 
individuals to whom a candidate vaccine was given immediately and individuals from whom 
it was withheld for a while; for the reasons mentioned above, the former were clearly dealt 
better prospects.
Ironically, a formal requirement of equipoise in all Ebola clinical trials would have also 
banned the safety and immunogenicity studies of Ebola vaccines that were performed on 
volunteers geographically distant from the outbreak earlier than the efficacy trials we are 
discussing.35–37 For any volunteer at low risk of infection, a lower dose was clearly 
preferable, and the higher dose sometimes carried negative side effects.3538 While few 
equipoise supporters expect equipoise in toxicity trials, most arguments for equipoise in 
efficacy trials (eg, that study participants should be treated as patients)39 would condemn 
even toxicity trials that lack equipoise.
Put in the most general way, in any possible randomised controlled trial for a promising 
intervention, allocation to arms almost inevitably prompts a disparity between trial 
participants. And in practice, virtually any intervention that passes Phase I and Phase II trials 
and is considered for Phase III would be considered promising, prompting such a disparity. 
That disparity is as inevitable in individually randomised trials as it is in cluster-randomised 
ones; it remains inevitable whether control is temporal or spatial or by type of intervention 
or based on the difference between intervention and placebo. Any randomised controlled 
trial of a devaluating intervention (namely, one that it is better to receive early than late) that 
initially seems more promising for participants than placebo must place some participants in 
a group that immediately on allocation to arms will have worse prospects than some other 
participants—in violation of equipoise. Shy of fully compensating for that worse prospect, 
for example, through indirect benefits like money if and when those can fully compensate or 
through active control that decreases overall risk as much as the study intervention would, 
that disparity stands. Call this the rule of nearly inevitable disparity within all randomised 
controlled trials.
In the case of Ebola vaccine efficacy, prior to every trial considered, the intervention seemed 
more promising than placebo, and devaluating. As the rule above states, that just meant that 
trial participation was more promising in some arms than in others, in violation of equipoise
—both in iRCTs and in stepped-wedge and ring vaccination trials. The differences between 
iRCT and other designs lay in the details of how they transgressed equipoise, not in whether 
they did.
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FOR ZIKA AND FOR MANY FUTURE EMERGING INFECTIONS, EVEN MANY 
OPPONENTS OF PLACEBO-CONTROLLED TREATMENT TRIALS COULD 
SUPPORT VACCINE IRCTS
Bioethicists suspicious of most placebo control in low/middle-income countries could also 
support typical vaccine efficacy iRCTs, both for Ebola and for many other emerging 
infections. First, some iRCTs lack a placebo arm and may even fulfil equipoise. Second, 
even a placebo-controlled iRCT can benefit controls, absent compensation and other external 
benefits, for example when the vaccine is safety-tested and healthcare in the trial is superior 
to conditions in surrounding clinics, or when detection and treatment are faster for those 
under surveillance by the trial or when controls receive the candidate vaccine shortly after 
the trial. Third, rarely, even a placebo-controlled iRCT can fulfil equipoise—when there is 
indication that the vaccine, which was safe in unexposed persons, might be unsafe in 
exposed persons, say by exacerbating risk of infection on exposure.40 Fourth, in a placebo-
controlled trial of a vaccine candidate, even for a highly lethal disease, being in the control 
arm is no death sentence because participants are rarely, if ever, known to be exposed or 
infected (table 1 row 3e; at the peril of non-interpretability, trials are not the place to provide 
postexposure prophylaxis or compassionate use). Fifth, for an emerging infection, usually no 
vaccination exists, and even the international research ethics document most doubtful of 
placebo control, the Declaration of Helsinki, agrees that ‘Where no proven intervention 
exists, the use of placebo, or no intervention, is acceptable’ (§33); against one 
commentator,8 when a trial seeks to develop pandemic countermeasures, ‘acceptable’ should 
clearly be considered good enough.41 Finally, when experimental vaccine supply is limited 
(as it often will be in emerging infections), distributive equality is arguably better served by 
a randomised scheme of allocation among a larger number of at-risk people than by 
deterministic allocation to a subset of them. iRCTs achieve that.
CONCLUSION
Most ethicists agree that public health emergencies can justify some diversion from fairness 
towards individuals, with or without their informed consent. Fortunately, emerging infection 
vaccine efficacy iRCTs do not usually demand any such diversion. Far from being harmed in 
the pursuit of lofty scientific standards, iRCT participants would often gain several indirect 
and direct benefits and privileged prospects compared with their alternatives either outside 
trials or in trials favoured by iRCT opponents, and compared with those of non-participating 
individuals at risk.
The assumption that there must be something unfair or unethical about iRCTs was false for 
Ebola vaccines. It will be sheer dogma for vaccines in Zika and in many future outbreaks of 
emerging infection—especially for ones with high lethality or with no existing cure or 
vaccination.
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APPENDIX A: FEASIBILITY
In late 2014, feasibility challenges to iRCTs were also raised. While the primary focus of the 
present article is ethics, the foremost feasibility challenges were arguably resolvable or no 
worse than ones posed by alternative designs.
Obtaining consent to randomisation, tracking who belongs to which arm and keeping 
participants blinded can prove challenging when trust and literacy are low.35 But study 
participants could be (and at the time were planned to be) primarily literate and trusting 
health workers;4243 anthropologists confirmed that participants in the region could be 
educated about randomisation4445 and blinding was impossible under cluster-randomised 
alternatives to iRCTs proposed at the time in which sites would either deliver or not deliver 
vaccination during each period.3 Cluster-randomised approaches were also suggested as 
ways to bring the trial to areas of high transmission and to use vaccine doses immediately as 
they became available, but this could be accomplished with an iRCT design.17 Traditional 
iRCTs might take long,35 but less-efficient designs typically take longer, and iRCTs could 
use adaptive and group-sequential elements to expedite evaluation and focus the study where 
cases are numerous.1517 Placebo-controlled iRCTs were specifically said in this context to 
damage trust.546 But iRCTs need not involve placebo control; in one Ebola vaccine placebo-
controlled iRCT, initial distrust37 turned into high levels of adherence; and trust could 
plunge if a suboptimally tested vaccine were rolled out to wide populations then discovered 
to have been ineffective or toxic.
A stepped-wedge trial and standard cluster randomisation between clinics would be 
spatiotemporally confounded, leading to inefficiency,47 as well as to a risk of bias if such 
factors were not perfectly accounted for in the analysis. The West African Ebola outbreak, 
for example, turned out to have unpredictable surges and declines, fading in some places 
while flaring in others, making the proposed comparisons of different periods or different 
sites less interpretable. A hybrid design could incorporate some of the logistical advantages 
of stepped-wedge into an adaptive iRCT.17
Ring vaccination is the strategy that successfully demonstrated vaccine effectiveness under 
very challenging conditions,18 and it might be deemed most feasible. But in future emerging 
disease outbreaks, this approach might not provide confident effectiveness estimates. For 
example, the strategy might be less useful with modestly effective vaccines; when the 
identification and diagnosis of infectious persons is difficult due to asymptomatic or 
presymptomatic transmission; when stigma hinders case identification and when other 
factors hinder the effective design of a trial. High levels of population or vector mobility 
could reduce the relevance of geographical or social-contact definitions of rings. The 
candidate vaccine that worked in a ring delivery model might fail under more standard 
population-wide vaccination models, for instance if its efficacy is short-lived or is greatest 
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when given postexposure. Given these uncertainties, the cluster-randomised ring-vaccination 
trial strategy might not be the strategy of choice for all future emerging diseases. Finally, it 
would, in principle, be possible to test ring vaccination with individual randomisation (that 
is, with vaccinees and controls compared within each ring).
From a scientific and feasibility standpoint, then, iRCTs of some form or another retain great 
attraction.
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Table 1
During the 2014–2015 outbreak, were these conditions consistent (✓) or inconsistent (–) with placebo 
individually randomised controlled trials (placebo iRCT), active iRCT and stepped-wedge/ring-vaccination 
designs of efficacy studies for candidate Ebola vaccines?
Placebo
iRCT
Active
iRCT
Stepped-wedge or
ring-vaccination trial
1. General
  a. The study intervention is needed urgently for many people. ✓ ✓ ✓
  b. No study assignment involves a procedure that is expected to actively harm any participant 
more than it directly benefits her.
✓ ✓ ✓
  c. No intervention for the condition studied is approved (and available to candidate 
participants).
✓ ✓ ✓
2. Participant access to study intervention
  a. All participants receive the study intervention during the trial—except ones who die or get 
infected before the intervention reaches them.
– – ✓
  b. All participants receive the study intervention during the trial or shortly thereafter—except 
ones who die or get infected before the intervention reaches them.
✓ ✓ ✓
  c. For any prespecified level of statistical power to detect a given effect size, typically the 
number of participants who die or get infected before the study intervention reaches them is 
minimal.
✓ ✓ –
3. Impact on participants’ prospects
  a. Participation improves medical prospects for each participant (both before and immediately 
after randomisation) more than any alternative available outside the trial.
✓ ✓ ✓
  b. Participation improves medical prospects for each participant (both before and immediately 
after randomisation) more than any alternative, including even alternatives that compromise trial 
efficiency or validity.
– – –
  c. Participation improves medical prospects for each participant (both before and immediately 
after randomisation), making their prospects better than those of relevant non-participants.
✓ ✓ ✓
  d. Equipoise (understood here as equal medical prospects in all arms immediately after 
randomisation) obtains.
– – –
  e. In no trial arm do the typical participants have grim medical prospects (immediately after 
randomisation).
✓ ✓ ✓
For simplicity, the table assumes trials with two equally sized arms.
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